Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Accumulated Expenses (2016 - 2025)

Lifecore Biomedical, Inc. \De\ (LFCR) has 15 years of Accumulated Expenses data on record, last reported at $22.0 million in Q2 2025.

  • For Q2 2025, Accumulated Expenses fell 2.57% year-over-year to $22.0 million; the TTM value through May 2025 reached $22.0 million, down 2.57%, while the annual FY2025 figure was $22.0 million, 2.57% down from the prior year.
  • Accumulated Expenses reached $22.0 million in Q2 2025 per LFCR's latest filing, up from $19.7 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $22.5 million in Q2 2024 and bottomed at $3.4 million in Q4 2023.
  • Average Accumulated Expenses over 5 years is $8.7 million, with a median of $6.6 million recorded in 2021.
  • Peak YoY movement for Accumulated Expenses: plummeted 53.64% in 2023, then skyrocketed 443.74% in 2024.
  • A 5-year view of Accumulated Expenses shows it stood at $7.2 million in 2021, then crashed by 36.21% to $4.6 million in 2022, then fell by 27.12% to $3.4 million in 2023, then soared by 38.07% to $4.6 million in 2024, then skyrocketed by 374.15% to $22.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $22.0 million in Q2 2025, $19.7 million in Q1 2025, and $4.6 million in Q4 2024.